First ‘NOAC’ antidote, Praxbind, counting down for domestic introduction

The first NOAC antidote is expected to be introduced in Korea.

According to the industry concerned on the 17^th, Boehringer Ingelheim recently turned in the approval application of ‘Praxbind(idaruxizumab),’ an antibody of the oral anti-coagulant(NOAC) ‘Pradaxa(dabigatran),’ to the Ministry of Food and Drug Safety.

After its US FDA’s approval at the end of the last year, the company has promptl...